Home › Research › Topics › rapamycin
rapamycin
5 studies tagged rapamycin, dated 2010-11-01 to 2025-05-20. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Rapamycin treatment for Alzheimer's disease and related dementias: a pilot phase 1 clinical trial 2025-05-20
- Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial 2019-11-25
- The Molecular Mechanism of Glucagon-Like Peptide-1 Therapy in Alzheimer's Disease, Based on a Mechanistic Target of Rapamycin Pathway 2017-07-01
Studies
5 studies carry this tag.
Date range
2010 to 2025
Top journals
- Antioxidants & redox signaling 1
- CNS drugs 1
- Communications medicine 1
- GeroScience 1
- Oxidative medicine and cellular longevity 1
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
45/100
Rapamycin is not detectable in the CSF before or after treatment, but several Alzheimer's disease and inflammatory biomarkers increase after treatment.
-
Aging is a major risk factor for the majority of human diseases, and the development of interventions to reduce the intrinsic rate of aging is expected to reduce the risk for age-related diseases including cardiovascular disease, cancer, and dementia.
-
The mechanistic target of rapamycin (mTOR) is an important molecule that connects aging, lifespan, energy balance, glucose and lipid metabolism, and neurodegeneration.
-
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder and represents one of the most disabling conditions.
-
The mammalian target of rapamycin (mTOR) and its associated cell signaling pathways have garnered significant attention for their roles in cell biology and oncology.